ClinicalTrials.gg
CompletedNCT00603980Updated Apr 22, 2026Results posted

Staccato Alprazolam Abuse Liability

A Phase 1 interventional study of Inhaled placebo + oral placebo and Inhaled alprazolam 0.5 mg in Abuse Liability of Staccato Alprazolam, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.

Read the detailed description

The Phase 1 clinical study compared the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo in 14 subjects with a history of sedative abuse. Subjects who met the inclusion/exclusion criteria received 2 mg of oral alprazolam and matching placebo over 2 sessions. Those who demonstrated greater liking for alprazolam versus placebo were eligible to participate in the study.

02

Conditions studied

  • Abuse Liability of Staccato Alprazolam
03

In context

Lead sponsor

Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between the ages of 18 to 55 years, inclusive, who have a history of substance abuse or dependence on barbiturates and/or benzodiazepine receptor agonists for their intoxicating effects

Exclusion criteria

Exclusion Criteria:

  • Subjects with a significant current psychiatric illness or taking any psychotropic prescription medications for therapeutic uses.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Other
    Treatment sequence 1

    Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 2

    Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 3

    Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 4

    Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 5

    Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 6

    Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 7

    Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 8

    Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 9

    Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 10

    Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 11

    Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 12

    Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 13

    Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

  • Other
    Treatment sequence 14

    Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg

    Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session

Interventions

06

What researchers measure

Primary outcomes

  1. Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"

    The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, "Rate the degree to which you would like to take the drug again", with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much

    Time frame: End of day for each of the 7 crossover treatments

Secondary outcomes

  1. EDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect"

    The within patient rank (1-7) of End of Day question number 2 (of primary interest), "Rate your overall liking of the drug effect", response options range from -4 to +4: * 4=Dislike very much * 3=Dislike quite a bit * 2=Dislike somewhat * 1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT * 1=Like, but not very much * 2=Like somewhat * 3=Like quite a bit * 4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: End of day for each of the 7 crossover treatments

  2. EDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street".

    EDQ question number 6 (of primary interest)," Estimate the amount of money you think the drug you took today would be worth on the street".

    Time frame: End of day for each of the 7 crossover treatments

  3. EDQ Question Number 1, "Rate the Overall Strength of the Drug Effect"

    The within patient rank (1-7) of End of Day question number 1, "Rate the overall strength of the drug effect", response options range from 0-4: 0=No drug effect at all 1. Possible mild effect, but not sure 2. Definite mild effect 3. Moderate strong drug effect 4. Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: End of day for each of the 7 crossover treatments

  4. EDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?"

    EDQ question number 7," What would you be willing to pay for today's drug?"

    Time frame: End of day for each of the 7 crossover treatments

  5. Maximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours)

    The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4: "No drug effect at all"=0, "Possible mild effect, but not sure"=1, "Definite mild effect"=2, "Moderate strong drug effect"=3, "Very strong drug effect"=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: DEQ was assessed at the 10 time points (predose through 9 hours)

  6. Maximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours)

    The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4: "Dislike very much"=-4, "Dislike quite a bit"=-3, "Dislike somewhat"=-2, "Dislike, but not very much"=-1, "NEUTRAL OR NO EFFECT"=0, "Like, but not very much"=1, "Like somewhat"=2, "Like quite a bit"=3, "Like very much"=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: DEQ was assessed at the 10 time points (predose through 9 hours)

  7. Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness

    The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point. The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  8. Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor

    The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  9. Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor

    The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  10. Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture

    The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  11. Observer Rated Questionnaire 5) Maximum of Speech

    The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  12. Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation

    The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  13. Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal

    The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

  14. Observer Rated Questionnaire 8) Maximum of Drug Strength

    The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

    Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)

07

Results

Posted Jan 2, 2020
Limitations and caveats
A limitation of the current study was the lack of assessment of drug plasma levels. The differences in abuse potential measures may be due to differences in absorption, peak drug plasma levels, or other PK parameters

Participant flow

Study Qualification
Participant flow — Study Qualification
MilestoneAll Subjects Entering
Started31
Completed15
Not completed16
Withdrew: Protocol violation3
Withdrew: Inconsistent data reporting13
Main Study
Participant flow — Main Study
MilestoneAll Subjects Entering
Started15
Completed14
Not completed1
Withdrew: 14th subject completed trial1

Outcome measures

PrimaryResponse to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"

The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, "Rate the degree to which you would like to take the drug again", with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much

Time frame:
End of day for each of the 7 crossover treatments
Reported as:
Least squares mean · units on a scale
Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"
units on a scalePlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"0 ± 0.3491.714 ± 0.3492.143 ± 0.3492.286 ± 0.3491.00 ± 0.3491.714 ± 0.3492.214 ± 0.349
SecondaryEDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect"

The within patient rank (1-7) of End of Day question number 2 (of primary interest), "Rate your overall liking of the drug effect", response options range from -4 to +4: * 4=Dislike very much * 3=Dislike quite a bit * 2=Dislike somewhat * 1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT * 1=Like, but not very much * 2=Like somewhat * 3=Like quite a bit * 4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
End of day for each of the 7 crossover treatments
Reported as:
Least squares mean · Rank across the 7 treatments
EDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect"
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
EDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect"1.679 ± 0.3494.214 ± 0.3494.429 ± 0.3494.607 ± 0.3492.571 ± 0.3494.857 ± 0.3495.643 ± 0.349
SecondaryEDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street".

EDQ question number 6 (of primary interest)," Estimate the amount of money you think the drug you took today would be worth on the street".

Time frame:
End of day for each of the 7 crossover treatments
Reported as:
Least squares mean · Dollars ($)
EDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street".
Dollars ($)PlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
EDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street".1.750 ± 0.4023.571 ± 0.4027.071 ± 0.4028.714 ± 0.4022.857 ± 0.4024.286 ± 0.4028.571 ± 0.402
SecondaryEDQ Question Number 1, "Rate the Overall Strength of the Drug Effect"

The within patient rank (1-7) of End of Day question number 1, "Rate the overall strength of the drug effect", response options range from 0-4: 0=No drug effect at all 1. Possible mild effect, but not sure 2. Definite mild effect 3. Moderate strong drug effect 4. Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
End of day for each of the 7 crossover treatments
Reported as:
Least squares mean · Rank across the 7 treatments
EDQ Question Number 1, "Rate the Overall Strength of the Drug Effect"
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
EDQ Question Number 1, "Rate the Overall Strength of the Drug Effect"1.429 ± 0.3173.536 ± 0.3174.821 ± 0.3175.429 ± 0.3172.893 ± 0.3174.143 ± 0.3175.750 ± 0.317
SecondaryEDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?"

EDQ question number 7," What would you be willing to pay for today's drug?"

Time frame:
End of day for each of the 7 crossover treatments
Reported as:
Least squares mean · Dollars ($)
EDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?"
Dollars ($)PlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
EDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?"1.607 ± 0.3873.821 ± 0.3874.571 ± 0.3875.179 ± 0.3872.964 ± 0.3874.107 ± 0.3875.750 ± 0.387
SecondaryMaximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours)

The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4: "No drug effect at all"=0, "Possible mild effect, but not sure"=1, "Definite mild effect"=2, "Moderate strong drug effect"=3, "Very strong drug effect"=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
DEQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Maximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours)
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Maximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours)1.571 ± 0.3403.143 ± 0.3404.714 ± 0.3405.536 ± 0.3403.036 ± 0.3404.250 ± 0.3405.750 ± 0.340
SecondaryMaximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours)

The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4: "Dislike very much"=-4, "Dislike quite a bit"=-3, "Dislike somewhat"=-2, "Dislike, but not very much"=-1, "NEUTRAL OR NO EFFECT"=0, "Like, but not very much"=1, "Like somewhat"=2, "Like quite a bit"=3, "Like very much"=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
DEQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Maximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours)
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Maximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours)1.607 ± 0.3433.500 ± 0.3434.536 ± 0.3435.536 ± 0.3432.893 ± 0.3434.250 ± 0.3435.679 ± 0.343
SecondaryObserver Rated Questionnaire 1) Maximum of Sedation/Sleepiness

The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point. The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness2.250 ± 0.3133.679 ± 0.3134.607 ± 0.3134.714 ± 0.3133.929 ± 0.3134.000 ± 0.3134.821 ± 0.313
SecondaryObserver Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor

The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor2.464 ± 0.2872.964 ± 0.2874.643 ± 0.2876.357 ± 0.2872.821 ± 0.2873.571 ± 0.2875.179 ± 0.287
SecondaryObserver Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor

The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · units on a scale
Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor
units on a scalePlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor2.536 ± 0.2823.036 ± 0.2824.607 ± 0.2826.393 ± 0.2822.714 ± 0.2823.786 ± 0.2824.929 ± 0.282
SecondaryObserver Rated Questionnaire 4) Maximum of Muscle Relaxation Posture

The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture2.750 ± 0.3372.893 ± 0.3373.964 ± 0.3376.250 ± 0.3372.929 ± 0.3372.929 ± 0.3372.929 ± 0.337
SecondaryObserver Rated Questionnaire 5) Maximum of Speech

The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 5) Maximum of Speech
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 5) Maximum of Speech2.214 ± 0.2842.893 ± 0.2844.786 ± 0.2846.393 ± 0.2843.071 ± 0.2843.071 ± 0.2845.357 ± 0.284
SecondaryObserver Rated Questionnaire 6) Maximum of Confusion/Disorientation

The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation1.929 ± 0.2822.821 ± 0.2824.893 ± 0.2826.429 ± 0.2823.393 ± 0.2823.107 ± 0.2825.429 ± 0.282
SecondaryObserver Rated Questionnaire 7) Maximum of Stimulation/Arousal

The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal
Rank across the 7 treatmentsPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal3.964 ± 0.0873.964 ± 0.0873.964 ± 0.0873.964 ± 0.0873.964 ± 0.0873.964 ± 0.0874,214 ± 0.087
SecondaryObserver Rated Questionnaire 8) Maximum of Drug Strength

The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect

Time frame:
ORQ was assessed at the 10 time points (predose through 9 hours)
Reported as:
Least squares mean · Rank across the 7 treatments
Observer Rated Questionnaire 8) Maximum of Drug Strength
Rank across the 7 treatmentsOral Alprazolam 1 mgPlaceboOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mg
Observer Rated Questionnaire 8) Maximum of Drug Strength2.786 ± 0.2861.714 ± 0.2864.571 ± 0.2866.321 ± 0.2863.000 ± 0.2863.929 ± 0.2865.679 ± 0.286

Adverse events

Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/15 (0%)0/15 (0%)0/15 (0%)
Oral Alprazolam 1 mg0/15 (0%)0/15 (0%)0/15 (0%)
Oral Alprazolam 2 mg0/14 (0%)0/14 (0%)0/14 (0%)
Oral Alprazolam 4 mg0/15 (0%)0/15 (0%)1/15 (6.7%)
Inhaled Alprazolam 0.5 mg0/14 (0%)0/14 (0%)0/14 (0%)
Inhaled Alprazolam 1 mg0/15 (0%)0/15 (0%)0/15 (0%)
Inhaled Alprazolam 2 mg0/15 (0%)0/15 (0%)0/15 (0%)
Qualifying Session 2 mg Oral0/28 (0%)0/28 (0%)0/28 (0%)
Qualifying Session Oral Placebo0/28 (0%)0/28 (0%)1/28 (3.6%)
Most frequent other events
Most frequent other events
EventPlaceboOral Alprazolam 1 mgOral Alprazolam 2 mgOral Alprazolam 4 mgInhaled Alprazolam 0.5 mgInhaled Alprazolam 1 mgInhaled Alprazolam 2 mgQualifying Session 2 mg OralQualifying Session Oral Placebo
SedationNervous system disorders0/150/150/141/150/140/150/150/280/28
HypertensionVascular disorders0/150/150/140/150/140/150/150/281/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Qualifying Session (Includes Crossover Group)
<=18 years0
Between 18 and 65 years31
>=65 years0
Age, Continuous
Age, Continuous(years)Qualifying Session (Includes Crossover Group)
Mean38.032 ± 38.032
Sex: Female, Male
Sex: Female, Male(Participants)Qualifying Session (Includes Crossover Group)
Female9
Male22
Region of Enrollment
Region of Enrollment(participants)Qualifying Session (Includes Crossover Group)
United States31
08

Study locations

1 site
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21224, United States
09

References and documents

Publications

  • Reissig CJ, Harrison JA, Carter LP, Griffiths RR. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology (Berl). 2015 Mar;232(5):871-83. doi: 10.1007/s00213-014-3721-0. Epub 2014 Sep 9. PubMed 25199955 ↗

Individual participant data

Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 11 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2008
First posted
Jan 29, 2008
Start
Jan 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Jan 2, 2020
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00603980
Lead sponsor
Nova Pneuma Inc.
Responsible party
Sponsor
First posted
Jan 29, 2008
Start date
Jan 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Jan 2, 2020
Last update
Apr 22, 2026

Study contacts

Roland R Griffiths, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alprazolam

Start the discussion